Assembly Biosciences (NASDAQ:ASMB) Receives “Buy” Rating from HC Wainwright

Assembly Biosciences (NASDAQ:ASMB)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Thursday,Benzinga reports. They presently have a $50.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price objective points to a potential upside of 74.40% from the company’s current price.

A number of other brokerages have also commented on ASMB. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Wednesday, January 21st. Wall Street Zen upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Assembly Biosciences has an average rating of “Moderate Buy” and a consensus target price of $41.75.

Assembly Biosciences Stock Up 1.6%

ASMB opened at $28.67 on Thursday. The firm has a market capitalization of $454.79 million, a P/E ratio of -38.74 and a beta of 1.11. The stock has a fifty day moving average of $27.98 and a 200-day moving average of $29.72. Assembly Biosciences has a 12-month low of $7.75 and a 12-month high of $39.71.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, March 19th. The biopharmaceutical company reported $2.48 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.51) by $2.99. The business had revenue of $42.47 million for the quarter, compared to the consensus estimate of $7.42 million. Assembly Biosciences had a negative return on equity of 5.63% and a negative net margin of 8.47%. On average, analysts expect that Assembly Biosciences will post -6.87 earnings per share for the current fiscal year.

Institutional Trading of Assembly Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of ASMB. Seven Fleet Capital Management LP acquired a new stake in Assembly Biosciences during the fourth quarter valued at $147,000. Virtus Investment Advisers LLC acquired a new position in Assembly Biosciences in the 4th quarter worth about $251,000. Susquehanna Portfolio Strategies LLC acquired a new position in Assembly Biosciences in the 4th quarter worth about $473,000. Superstring Capital Management LP purchased a new stake in shares of Assembly Biosciences during the 4th quarter worth about $2,220,000. Finally, Millennium Management LLC raised its stake in shares of Assembly Biosciences by 354.6% during the 4th quarter. Millennium Management LLC now owns 98,221 shares of the biopharmaceutical company’s stock worth $3,340,000 after purchasing an additional 76,613 shares in the last quarter. 19.92% of the stock is currently owned by hedge funds and other institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.